

**The differences of the effects on lipid-lowering actions  
and glucose metabolisms  
between Rosuvastatin and Atorvastatin  
in Japanese diabetic patients with hyperlipidemia.**



**- Lipid lowering with highly potent Statins in hyperlipidemia  
with Type 2 diabetes patiENts –**

**Hisao Ogawa, Yoshihiko Saito, Hideaki Jinnouchi, Masahiro Sugawara, Seigo Sugiyama, Izuru Masuda, Kunihiro Matsui, Hisao Mori, Masako Waki, Hiroataka Watada, Minoru Yoshiyama on behalf of the LISTEN Study investigators**

**ESC Congress 2014  
August 31, 2014  
Barcelona – Spain**



# DECLARATION OF INTEREST

- honoraria, other research support


# Conflict of interest disclosure

**LISTEN study was funded by the Non-Profit Organization, Hokkaido Kenkoukagaku Institute and the Investigator Sponsored Study Program of AstraZeneca K.K.**

**Hisao Ogawa, MD, PhD has received research supports or honoraria or both from Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Company, Limited, Dainippon Sumitomo Pharma Co., Ltd., Kowa Company, Ltd., MSD K.K., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., and Takeda Pharmaceutical Company Limited.**



# Study design





**Primary endpoints** : Percent Change in non-HDL-C level  
Change of HbA1c level

**Number of study sites** : 132 sites in Japan



# Lipid parameters



● Atorvastatin  
● Rosuvastatin



No. of participants	0 month	3 months	6 months	12 months
Atorvastatin	504	494	482	472
Rosuvastatin	514	493	485	468



# Glucose metabolism parameters




No. of participants	0 month	3 months	6 months	12 months
Atorvastatin	504	494	482	472
Rosuvastatin	514	493	485	468

No. of participants	0 month	3 months	6 months	12 months
Atorvastatin	503	493	481	471
Rosuvastatin	514	492	485	468



# The cumulative incidence of diabetes treatment intensification



	No. at Risk	0	3	6	12 (months)
Atorvastatin	504	471	451	182	
Rosuvastatin	514	480	466	190	



# Conclusions

**Rosuvastatin did not reduce non-HDL-C compared with Atorvastatin, but overall did reduce LDL-C significantly.**

**The intensification of diabetic treatments was significantly less frequent in the Rosuvastatin group than in the Atorvastatin group.**

**Further prospective studies are required to confirm the differences in the effects on diabetes among statins.**

